HANGZHOU, China, Aug. 6, 2018 /PRNewswire/ -- Adlai Nortye Biopharma Co., Ltd. ("Adlai Nortye" or "the Company"), a leading biopharmaceutical company in China, announced that Lars E. Birgerson, M.D., Ph.D., joins the company as Chief Development Officer (CDO) and President & CEO of Adlai Nortye USA Inc on July 1(st). In his role, Dr. Birgerson will provide leadership and direction to advance Adlai Nortye's pipeline of clinical development programs in cancer treatment, with primary focus on immuno-oncology.
Along with significant domain experience in immuno-oncology and global clinical development, Dr. Birgerson brings extensive knowledge from commercial, business development, and medical affairs, both globally and in the U.S. Prior to Adlai Nortye, Dr. Birgerson served as Senior Vice President, Medical R&D at Bristol-Myers Squibb (BMS). At BMS, Dr. Birgerson was responsible for realignment of the Medical Affairs and Health Economics/Outcomes teams toward emerging opportunities in Specialty Medicine, particularly immuno-oncology.
Dr. Birgerson is a physician with more than 25 years of biopharmaceutical industry experience in senior positions for a number of leading companies, including Bristol-Myers Squibb, Genentech, Roche, and Pharmacia. He received his M.D. and Ph.D. and completed residencies in Obstetrics and Gynecology, General Surgery, Gynecological Oncology, and Urological Surgery at Uppsala University in Sweden. He is a dual citizen of the United States and Sweden.
"I am very excited to be joining the Adlai Nortye team in building a Global Biotech Company with Chinese roots. Adlai Nortye is a challenger in biotech with a very exciting portfolio of middle and late stage compounds, which holds considerable promise for patients," said Dr. Birgerson. "I look forward to working closely with the many talents within Adlai Nortye to bring more innovative treatments to help enhance the lives of cancer patients around the world."
"We are very fortunate to have the leadership of Dr. Birgerson in our clinical development programs and the operations of our US organization," said Carsten Lu, CEO of Adlai Nortye. "At Adlai Nortye, our goal is to grow into a globally aligned, world-class biotech firm. I am confident that Dr. Birgerson, with his credentials and track record, will provide the leadership needed, adding to the strengths of the current Adlai Nortye team to help us achieve that goal and reach an even greater level of success."
About Adlai Nortye
Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs in the field of oncology/immuno-oncology. Our mission is to improve patient lives by identifying and acquiring differentiated innovative medicines that help people live better and longer. Through close collaboration with global partners, we have successfully positioned ourselves in the fields of immuno-oncology/oncology and have several programs ongoing from early pre-clinical to phase 3 ready.
For further information about Adlai Nortye, please visit: http://www.adlainortye.com/en.php [http://www.adlainortye.com/en.php]
CONTACT: Dan Guo,+86-183-5816-8416, email@example.com